Skip to main content

Table 2 Tumor response in each line of treatment

From: Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

  Total number CR PR SD PD NE ORR DCR
1st-line treatment
All patients 50 1 4 12 27 6 10.0% 34.0%
  Gemcitabine 24 0 1 5 15 3 4.2% 25.0%
  S-1 12 0 0 5 6 1 0.0% 41.7%
  Gemcitabine plus nab-paclitaxel 6 0 2 1 2 1 33.3% 50.0%
  Gemcitabine plus S-1 2 0 0 0 2 0  
  FOLFIRINOX 2 0 1 0 1 0
  S-1 plus radiation 1 0 0 1 0 0
  Paclitaxel 1 1 0 0 0 0
  S-1 plus cisplatin 1 0 0 0 1 0
  Gemcitabine plus radiation 1 0 0 0 0 1
2nd-line treatment
All patients 13 0 1 4 4 4 7.7% 38.5%
  S-1 6 0 0 3 1 2 0.0% 50.0%
  Gemcitabine 2 0 0 0 1 1  
  Gemcitabine plus nab-paclitaxel 2 0 0 0 1 1
  FOLFIRINOX 2 0 1 1 0 0
  FOLFOX 1 0 0 0 1 0
3rd-line treatment
All patients 2 0 1 1 0 0  
  Gemcitabine 1 0 0 1 0 0
  Gemcitabine plus nab-paclitaxel 1 0 1 0 0 0
Cumulative total
All patients 65 1 6 17 31 10 10.8% 36.9%
  Gemcitabine 27 0 1 6 16 4 3.7% 25.9%
  S-1 18 0 0 8 7 3 0.0% 44.4%
  Gemcitabine plus nab-paclitaxel 9 0 3 1 3 2 33.3% 44.4%
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, PFS progression-free survival, CI confidence interval, NR not reached